enGene Holdings Inc. (NASDAQ:ENGN) Stock Rated “Hold” by Wall Street Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received a consensus recommendation of “Hold” from the fourteen brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.05.

Several brokerages recently commented on ENGN. Citigroup downgraded enGene from a “market perform” rating to a “hold” rating in a report on Friday. Citizens Jmp reiterated a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. Jefferies Financial Group raised shares of enGene to a “strong-buy” rating in a report on Tuesday. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised shares of enGene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday.

Key Stories Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Jefferies upgrade: Jefferies Financial Group upgraded enGene, potentially improving investor sentiment and signaling a more favorable view of the company’s prospects or valuation. The article does not specify the new rating or price target. enGene Upgraded at Jefferies Financial Group
• Positive Sentiment: Preclinical and clinical-case-study discussion: enGene presented data and case studies involving a surfactant bladder rinse intended to improve delivery of its treatment. Additional evidence supporting the company’s investigational platform could help its outlook, although the information remains early-stage and does not establish definitive clinical efficacy. enGene Discusses Preclinical Data and Clinical Case Studies
• Neutral Sentiment: Company materials: A Yahoo Finance page lists enGene press releases, but the supplied entry does not identify a specific new announcement likely to materially affect the shares. enGene press releases
• Negative Sentiment: Existing financial pressure remains: enGene’s latest reported quarterly loss missed analyst expectations, and analysts expect another substantial loss for the full year. This limits the impact of the upgrade and keeps execution, cash usage and clinical progress important risks for investors.

Institutional Investors Weigh In On enGene

Hedge funds have recently bought and sold shares of the business. SR One Capital Management LP purchased a new position in shares of enGene during the 2nd quarter valued at approximately $1,293,607. Eversept Partners LP raised its stake in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares in the last quarter. Renaissance Technologies LLC grew its stake in enGene by 651.1% in the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after purchasing an additional 135,318 shares in the last quarter. Siren L.L.C. increased its holdings in enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after buying an additional 1,916,895 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in enGene in the first quarter valued at about $409,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Trading Down 2.3%

ENGN opened at $1.67 on Monday. The firm has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.83. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 10.21.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Analysts forecast that enGene will post -1.81 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.